Checkpoint inhibitors and indications
Anti CTLA-4 antibody:
 • Ipilimumab: Malignant melanoma, Renal cell cancer
Anti-PD-1 antibody:
 • Nivolumab: Malignant melanoma, Non-small cell lung cancer, Renal cell cancer lymphoma, Head and neck cancer, Gastric cancer, Malignant mesothelioma, Colorectal cancer with high-frequency microsatellite instability (MSI-High), Esophageal cancer
 • Pembrolizumab: Non-small cell lung cancer, Hodgkin lymphoma, Urothelial cancer, Solid cancers with high-frequency microsatellite instability (MSI-High), Renal cell cancer, Head and neck cancer
Anti PD-L1 antibody:
 • Atezolizumab: Non-small cell lung cancer, Small cell lung cancer, Breast cancer
 • Durvalumab: Non-small cell lung cancer
 • Avelumab: Merkel cell carcinoma renal cell cancer

#Checkpoint #inhibitors #indications #oncology #pharmacology